What to Expect When Increasing Your Wegovy Dose: Side Effects Explained

What the STEP 1 trial data tell us about dose-step side effects

The clearest picture we have of how people respond to escalating Wegovy comes from the STEP 1 trial, published in the New England Journal of Medicine. The 68-week study reported that gastrointestinal events were the most common reason participants reduced or paused their dose, and those events clustered around dose increases, not steady-state periods. Nausea affected around 44% of participants on semaglutide versus roughly 16% on placebo; diarrhoea and vomiting were also more frequent in the treatment group.

That pattern makes biological sense. Semaglutide slows gastric emptying and acts on appetite centres in the brain. When the dose steps up, the body is effectively recalibrating to a stronger signal. The discomfort is real, but it is typically transient. Most people find symptoms ease considerably by the end of the second week at a new dose level.

The standard escalation schedule runs from 0.25 mg through 0.5 mg, then to 1.0 mg, a step that many people find brings a noticeable increase in side effects compared with the lower starting doses, before continuing through 1.7 mg and up to a 2.4 mg maintenance dose, with roughly four weeks at each level, a pace designed specifically to give the body time to adjust. The NHS semaglutide medicines page sets out what to expect at each stage and is worth reading before your next step.

Side effects at the 0.25 mg starting dose are usually the mildest; you can read a focused breakdown on the starting-dose side effects page if you are still at that point.

Which specific symptoms tend to flare after a dose increase

Across the full Wegovy dose schedule, the side effects that typically spike after each step-up form a fairly predictable cluster. Nausea is the most reported. Vomiting is less common but more disruptive when it occurs. Diarrhoea and constipation can alternate, the gut is doing something quite different to what it usually does, and it takes time to settle. Burping, reflux and a heavy feeling after small amounts of food are also widely reported, particularly in the first few days after a step-up.

Fatigue and mild headache can accompany the GI symptoms, partly because eating less means energy intake drops sharply in the short term. Staying well hydrated and keeping protein intake reasonable are practical priorities; your prescriber or a dietitian can advise on specific amounts for your situation.

Injection-site reactions (redness, mild swelling, brief discomfort) can occur at any dose level. Rotating sites (abdomen, thigh or upper arm) and letting the pen reach room temperature before injecting both help. The semaglutide dose-increase side effects page goes deeper on individual symptoms and how people manage them.

One practical note: if your dose increase lands just before a bank holiday or you're travelling, consider whether you'll have easy access to clinical support for that first week. Our prescribers hear this question most often around Christmas and Easter, planning ahead is worth it.

When Wegovy side effects after a dose increase need medical attention

Most symptoms are unpleasant rather than dangerous. Mild to moderate nausea, loose stools, or reduced appetite are expected and do not usually require you to contact anyone urgently. The situations that do warrant prompt medical help are different in character: they persist, intensify or involve organs beyond the gut.

Seek urgent medical help if you experience:

• Severe stomach pain that does not ease and radiates toward your back, this is the key warning sign for acute pancreatitis, a known though infrequent risk highlighted in the MHRA's January 2026 Drug Safety Update for GLP-1 medicines.
• Persistent vomiting that prevents you from keeping fluids down for more than a day, dehydration can strain the kidneys.
• Pain in the upper right abdomen that may suggest gallbladder involvement.
• Signs of a serious allergic reaction: facial swelling, difficulty breathing, rapid deterioration.
• Low mood, unusual thoughts, or any thoughts of self-harm, although these are not common, they are taken seriously and should be reported promptly.

For anything less urgent, contact our team through the support page or speak to your GP. Side effects can also be reported directly to the MHRA via the Yellow Card scheme, it matters for everyone on these medicines.

How your prescriber decides whether to continue, pause or adjust

No dose increase happens automatically at nume. Every repeat order goes through clinical re-review, a real prescriber reads your update and considers whether progression makes sense. If the 1.0 mg or 1.7 mg step has been harder than expected, there is no rule that says you must push to the next level on a fixed calendar. Staying at a tolerated dose for longer is a legitimate clinical choice; so is stepping back temporarily.

The decision framework is outlined on the dose increase guidance page, which covers what to expect and what your prescriber looks for before approving the next step. For a broader picture of how Wegovy works across the full treatment journey, the Wegovy treatment overview is the natural starting point.

If you have not yet started treatment and want to understand the process before committing, our prescribers discuss suitability and talk through the side-effect picture as part of every free consultation, with no obligation to proceed. You can start that conversation here.